June 2, 2025 – BioNTech has partnered with Bristol Myers Squibb to globally co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors. The two companies, under this agreement, will work jointly to accelerate the development of this clinical candidate.
BioNTech’s BNT327 is a next-generation bispecific antibody candidate that targets both VEGF-A and PD-L1. It is currently being assessed in several ongoing trials. This includes global Phase 3 trials for extensive stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCL).
Bristol Myers and BioNTech will jointly develop and commercialize BNT327 as monotherapy and in combination with other products. Both companies may independently develop BNT327 for additional indications and combinations, including with their own pipeline assets.
BMS will pay BioNTech $1.5 billion upfront and $2 billion in fixed payments through 2028. These tax-deductible costs will be booked as Acquired IPR&D Expense, with the $1.5 billion recorded in Q2.
BioNTech may earn up to $7.6 billion in milestone payments. Both companies will split development and manufacturing costs 50:50, with some exceptions. Profits and losses will also be shared equally.
Views and Statements
Bispecific antibody candidate BNT327 has the tendency to combat solid tumors without affecting the body's normal immune function. If successful, BNT327 could revolutionize the global cancer immunotherapy industry by offering patients an advanced treatment approach.
In the words of Ugur Sahin, CEO of BioNTech, “We believe BNT327 can become a key immuno-oncology backbone, surpassing single-mechanism checkpoint inhibitors and targeting multiple solid tumors. Our partnership with BMS, a leader in immuno-oncology, will accelerate and expand its development to unlock its full potential.”
Christopher Boerner, CEO of Bristol Myers Squibb, said, “Our expertise in immuno-oncology positions Bristol Myers Squibb to unlock the full potential of BNT327”. He further added, “We believe BNT327 holds significant promise in transforming the standard of care for patients with solid tumors.
Impact and Future Outlook
The billion-dollar alliance between Bristol Myers Squibb and BioNTech marks a pivotal advancement in cancer immunotherapy. This collaboration holds the promise of reshaping how solid tumors are treated.
This collaboration combines BioNTech’s innovative bispecific antibody BNT327, which targets VEGF-A and PD-L1, with Bristol Myers’ extensive immuno-oncology expertise. Together, they aim to develop more effective and durable cancer therapies.
With equal cost-sharing and profit-splitting, the partnership underscores a strong mutual commitment to accelerating development and global commercialization. If proven effective, BNT327 could become a next-generation backbone therapy. It would significantly expand treatment options and improve outcomes for patients with lung and other solid tumors.
Other immunotherapy companies and pharmaceutical giants may follow Bristol Myers and BioNTech’s suit to stay ahead of the competition. They might form partnerships and alliances to advance cancer therapies.
Sources:
News Outlet: Reuters
Company: Bristol-Myers Squibb Company
